CAS: 84625-59-2; 1-Benzhydryl-4-[3-(2-Phenyl-1,3-Dioxolan-2-yl)Propyl]Piperazine

该化合物是一种化学化合物,被归类为钙管阻塞器,主要用于治疗各种血管疾病,众所周知,它能够通过电压加热的钙渠道抑制钙的流入,这可能导致血管变异和改善血液流.该化合物经常被探讨其在治疗诸如偏头痛和周围血管疾病等病症方面的潜在好处.多塔里辛在水中表现出相对较低的溶解性,这可能会影响其生物利用率和药用动力学.其分子结构包括有助于其药理活动的具体功能组.与许多药物一样,多塔里津的功效和安全状况通过临床研究确定,并可能具有需要监测的副作用.

结构式图片

上下游产品

CAS号3308-98-3 2-(3-chloroprop... | CAS号841-77-0 二苯甲基哌嗪 | CAS号90-99-3 二苯基氯甲烷

合成工艺路线路线简述

  • 合成目标产物 Dotarizine 主要起始原料 Chlorodiphenylmethane
  • (文献来源)合成步骤主要原料 Chlorodiphenylmethane
📜二苯氯甲烷置于碳酸氢钠体系中,用 乙醇 作为反应溶剂,化学反应 48.0H,反应生成 多他利嗪
参考文献:Gubert; Braso; Sacristan,Arzneimittel-Forschung/drug Research,1987,Vol. 37,# 10,P. 1103-1107
标题:Gubert; Braso; Sacristan,Arzneimittel-Forschung/drug Research,1987,Vol. 37,# 10,P. 1103-1107

海关参考信息

专利信息


专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-2023271983-A1
优先权日:2020-07-29
标题 :Functionalized isonitriles and products, preparation and uses thereof
发明人:SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA
权利人:UNIV SANTIAGO COMPOSTELA
摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

专利号:US-9265748-B2
优先权日:2011-08-11
标题 :Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
发明人:RAILLARD STEPHEN P; MANTHATI SURESH K; JOSHI SUDHIR
权利人:XENOPORT INC
摘要:Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.

专利号:US-2015313865-A1
优先权日:2011-08-11
标 题:Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use

专利号:US-2014066501-A1
优先权日:2011-08-11
标 题:Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use

专利号:US-8580850-B2
优先权日:2011-08-11
标题 :Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Villarroya M, Gandía L, Lara B, Albillos A, López MG, García AG. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells. Br J Pharmacol. 1995 Jan;114(2):369-76. doi: 10.1111/j.1476-5381.1995.tb13236.x.
2: Novalbos J, Abad-Santos F, Zapater P, Cano-Abad MF, Moradiellos J, Sánchez- García P, García AG. Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+. Eur J Pharmacol. 1999 Feb 5;366(2-3):309-17. doi: 10.1016/s0014-2999(98)00916-9. 332(2):183-93. doi: 10.1016/s0014-2999(97)01073-x. 481(1):41-50. doi: 10.1016/j.ejphar.2003.09.013. 48(3):187-93. doi: 10.1159/000139178. 28(1):129-32. doi: 10.1016/s0306-3623(96)00177-2. 110(Pt 2):55-60. doi: 10.1007/978-3-7091-0356-2_11. 411(3):289-99. doi: 10.1016/s0014-2999(00)00897-9. 25(3):291-310. Spanish. 239(1-3):75-81. doi: 10.1016/0014-2999(93)90978-q. 19(5):343-50. 175(1):13-6. doi: 10.1016/s0022-510x(00)00275-6. 141(11):1209-12. doi: 10.1007/s007010050420. 128(3):621-6. doi: 10.1038/sj.bjp.0702853.
15: Kuridze N, Gajkowska B, Czernicki Z, Jurkiewicz J, Cervos-Navarro J. The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia. Folia Neuropathol. 1998;36(2):101-8. 22(2):229-32. doi: 10.1080/01616412.2000.11740664. 21(4):93-8. 23(3-4):93-9. 25(2):43-50. 520(1-3):1-11. doi: 10.1016/j.ejphar.2005.06.044.

合成参考文献


摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
摘要:Arzneimittel-Forschung. Drug Research., 37(1103), 1987 []
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知